For patients with symptomatic disease necessitating therapy, ibrutinib is frequently proposed depending on 4 phase III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 and various generally employed CIT mixtures, specifically FCR, bendamustine moreover rituximab and chlorambucil moreover obinutuzumab (ClbO).107–109 … Read More